A bioinformatics analysis method for detecting Mycoplasma pneumoniae and its 23S rRNA gene drug-resistant mutations

By constructing a human sequence database using bioinformatics analysis methods and employing software for comparison and statistical analysis of base composition, the problems of long detection time, high cost, and low accuracy in existing technologies for detecting Mycoplasma pneumoniae drug resistance have been solved. This approach enables rapid and accurate drug resistance detection, which is applicable to the clinical diagnosis and treatment of Mycoplasma pneumoniae.

CN118173169BActive Publication Date: 2024-11-26HANGZHOU LUOXI MEDICAL LAB CO LTD
View PDF 14 Cites 0 Cited by

Patent Information

Application Number
CN202410362034.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-28
Publication Date
2024-11-26
Estimated Expiration
2044-03-28

AI Technical Summary

Technical Problem

Existing technologies for detecting macrolide resistance in Mycoplasma pneumoniae suffer from problems such as long detection time, high cost, and low accuracy. In particular, traditional isolation and culture methods and molecular biology techniques such as PCR cannot achieve rapid and sensitive detection when primer design is inappropriate.

Method used

Using bioinformatics analysis methods, a human sequence database was constructed, and comparisons were performed using bwa and samtools software. The base composition of the 23S rRNA gene was statistically analyzed using bam-readcount and Python scripts to screen for drug-resistant mutation sites, avoiding bacterial isolation and culture, thus achieving rapid and accurate drug resistance detection.

Benefits of technology

This method enables highly sensitive, specific, and low-cost detection of Mycoplasma pneumoniae and its 23S rRNA drug resistance sites. The detection time is short, making it suitable for clinical diagnosis and treatment, and improving detection sensitivity and accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118173169B_ABST
    Figure CN118173169B_ABST
Patent Text Reader

Abstract

The present application belongs to the field of biomedicine, and specifically relates to a bioinformatics analysis method for detecting mutations in drug-resistant sites of Mycoplasma pneumoniae and its 23S rRNA gene. The present application uses a bioinformatics analysis method for high-throughput sequencing data of pathogenic metagenomics, and can quickly detect whether the sample is infected with Mycoplasma pneumoniae and the base mutations of the four sites 2063, 2064, 2067 and 2617 of the 23S rRNA gene. In the identification of Mycoplasma pneumoniae, compared with the traditional separation and culture method, the method provided by the present application is faster and less expensive; in the detection of drug-resistant mutations, it is also different from the traditional method of designing specific PCR primers for mutation sites; in addition, the present application also invents a mutation analysis method based on the base composition of the site, and no longer relies solely on ready-made mutation detection software; the method provided by the present application has the advantages of high detection sensitivity, strong specificity, good repeatability, and short time required, and is suitable for the detection of Mycoplasma pneumoniae and its 23S rRNA drug-resistant sites.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to a bioinformatics analysis method for detecting macrolide drug resistance sites of Mycoplasma pneumoniae. Background Art

[0002] Mycoplasma pneumoniae (MP) is a bacterium belonging to the order Mycoplasmaales. It is one of the common pathogens of the human respiratory tract, and the diseases it causes mainly include upper respiratory tract infection, pneumonia, bronchitis, etc. Mycoplasma pneumoniae pneumonia (MPP) is the most common community-acquired pneumonia in children aged 5 years and above in my country, accounting for 10% to 40% of community-acquired pneumonia in hospitalized children; the first choice of antibacterial drugs for the treatment of Mycoplasma pneumoniae infection in clinical practice is macrolide drugs, but with the widespread clinical use of this drug, its drug resistance has also continued to emerge and is gradually increasing. In addition, because Mycoplasma pneumoniae lacks a cell wall structure, it is inherently resistant to antibiotics that act on the cell wall, such as penicillins and cephalosporins.

[0003] At present, a large number of studies have shown that the mechanism of Mycoplasma pneumoniae's resistance to macrolides is mainly gene mutation, among which mutation of the 23S rRNA gene is one of the main reasons for its resistance to macrolides; the binding site of macrolides is in the 23S rRNA domain, and mutations in the gene sites of the 23S rRNA domain II and V will reduce the affinity between antimicrobial drugs and ribosomes, thereby making Mycoplasma pneumoniae resistant. The mutation sites that have been found include 2063, 2064, 2067 and 2617, among which A2063G positive is resistant to 14-ring macrolides, A2064G positive is resistant to 14- and 16-ring macrolides, C2617G positive is resistant to 14- and 15-ring macrolide antibiotics, and A2067G positive is resistant to josamycin.

[0004] Although there are many methods for detecting Mycoplasma pneumoniae and its drug resistance genes, the detection of Mycoplasma pneumoniae based on isolation and culture and drug sensitivity testing is undoubtedly the "gold standard". Although this method is reliable, it has many disadvantages such as slow growth of Mycoplasma pneumoniae, long culture cycle, high technical requirements, expensive separation costs, and low positive rate of isolation and culture, which makes clinical application difficult. In addition, the commonly used Mycoplasma pneumoniae resistance detection technology also includes molecular biology techniques represented by PCR, such as capillary electrophoresis, digital PCR and fluorescent quantitative PCR. The key to this method is to design specific primer probes for drug resistance sites, but often due to unreasonable primer design and insufficient specificity, it is impossible to achieve accurate, rapid and sensitive detection, so that practical application is greatly limited. Summary of the invention

[0005] In order to solve the above problems, the present application provides a bioinformatics analysis method for detecting Mycoplasma pneumoniae and its 23S rRNA gene resistance mutations, which does not require bacterial isolation and culture, avoids the bacterial culture failure that may occur in traditional methods, and can analyze a large amount of data in a relatively short time, thereby accelerating the detection of resistance gene mutations.

[0006] The method provided in this application specifically includes the following steps:

[0007] 1. Data preparation. The data that needs to be prepared include the Mycoplasma pneumoniae reference genome annotated in the NCBI database, the sequence of the 23SrRNA gene, the hg19 version of the human reference genome and transcriptome sequence, the Yanhuang No. 1 human genome, the T2T-CHM13 human reference genome sequence, the pathogen metagenomic (mNGS) clinical samples, and the second-generation sequencing data of negative control samples.

[0008] 2. Quality control of the next-generation sequencing data of pathogen metagenomic (mNGS) clinical samples and negative control samples. The specific quality control conditions are as follows:

[0009] (1) Removal of adapter sequences. During high-throughput sequencing, when the length of the inserted fragment is shorter than the sequencing read length, the adapter sequence will appear in the sequencing results and cause contamination. Therefore, it must be removed during quality control.

[0010] (2) remove the bases with base quality values ​​less than 30 at the beginning and end;

[0011] (3) Remove sequences containing N bases in the read;

[0012] (4) Remove sequences with a single base accounting for more than 80% or two bases accounting for more than 90%;

[0013] (5) Removal of repetitive sequences;

[0014] (6) Remove low-complexity sequences, or simple repetitive sequences. Low-complexity sequences are often high-incidence areas of sequencing errors and should be removed during quality control.

[0015] In this application, whether a sample can be used after quality control must meet the following conditions at the same time:

[0016] (1) The Q30 base data volume accounts for more than 80%;

[0017] (2) The contamination rate of the joints does not exceed 1%;

[0018] (3) The effective sequence length is not less than 45 bp;

[0019] (4) The amount of valid data should be greater than 70%.

[0020] 3. Construct a human sequence database. This application constructs a comprehensive human sequence database that is compatible with the Chinese race. In addition to the conventional human reference genome and transcriptome, it also adds the Yanhuang No. 1 genome sequence specifically for the Chinese race and the gapless version of the human genome sequence T2T-CHM13; the quality-controlled data is compared with the human sequence database, and the sequences in the comparison are removed, and the remaining are high-quality non-human sequences.

[0021] 4. Use bwa software to index the reference genome sequence of Mycoplasma pneumoniae, and align the high-quality non-human sequence in step 3 to the reference genome sequence, and use samtools software to sort and index the comparison results.

[0022] 5. Establish the screening conditions for the alignment sequences, extract the alignment sequences that meet the following conditions from the alignment results in step 4 and save them as Fastq format files for searching for drug-resistant mutations.

[0023] (1) The number of reads N with an average sequencing quality value greater than or equal to 30 and a mapping quality value (MAPQ value) greater than or equal to 30 mapped to the Mycoplasma pneumoniae reference genome is greater than or equal to 10;

[0024] (2) The number of reads with an average sequencing quality value greater than or equal to 30 and a mapping quality value (MAPQ value) greater than or equal to 30 that are mapped to the Mycoplasma pneumoniae reference genome is greater than or equal to 2, that is, the number of uniquely mapped reads is greater than or equal to 2;

[0025] (3) The ratio of the normalized aligned read numbers of the clinical sample and the negative control sample is greater than or equal to 5, that is, Foldchange is greater than or equal to 5; if there is no read detection that meets the conditions in the negative control sample, Foldchange is positive infinity.

[0026] The sample normalization method is as follows: Number of sequences after normalization = (20*N*0.000001) / sample size (unit M)

[0027] Then: Foldchange = the number of clinical sample sequences after homogenization / the number of negative control sample sequences after homogenization

[0028] 6. Use bwa software to index the 23S rRNA gene sequence, and compare the Fastq format sequence extracted in step 5 to the 23S rRNA genome, and use samtools software to sort and index the comparison results, and then generate the corresponding bam format file.

[0029] 7. Use bam-readcount software to count the number of A, C, G, T and N bases at the four sites 2063, 2064, 2067 and 2617 of the 23S rRNA gene from the bam file generated in step 6, where N represents the uncertain specific base during sequencing, and the sum of the numbers of ACGTN is the sequencing depth of the site.

[0030] 8. According to the established screening principles, screen the credible mutation results from the base composition results in step 7. The specific screening principles are as follows:

[0031] (1) The proportion of mutation sites in a single chain (positive or negative chain) shall not exceed 90%;

[0032] (2) The mutation frequency is greater than or equal to 50% and the number of mutation reads is greater than or equal to 2;

[0033] (3) the mutation frequency is greater than or equal to 5% and less than 50%, the number of mutation reads is greater than or equal to 2, and the total depth of mutation sites is greater than or equal to 10;

[0034] On the basis of satisfying (1), satisfying any one of conditions (2) and (3) is a credible mutation result.

[0035] Compared with the prior art, this application has the following beneficial effects:

[0036] (1) The method of the present invention has high sensitivity, strong specificity and good repeatability, and requires a short time. It is suitable for the detection of Mycoplasma pneumoniae and its 23S rRNA resistance sites. This method has broad application prospects in clinical diagnosis and treatment.

[0037] (2) In terms of Mycoplasma pneumoniae identification, compared with the traditional isolation and culture method, the method provided by the present invention is more efficient, faster and less costly; in terms of drug resistance detection, this method is also different from the traditional drug sensitivity test and specific PCR primer design method; in addition, the present invention has also built a set of mutation analysis methods, which starts from the base composition of the drug resistance site and greatly improves the detection sensitivity compared with the existing mutation detection software. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1This is a general flow chart of a bioinformatics analysis method for detecting Mycoplasma pneumoniae and its 23S rRNA gene resistance mutations provided in this application.

[0039] Figure 2 Flowchart for determining whether a patient is infected with Mycoplasma pneumoniae.

[0040] Figure 3 Flow chart for determining whether a mutation has occurred at the drug resistance site of the 23S rRNA gene.

[0041] Figure 4 This is a screenshot of the IGV of the LX23138762063 site of an actual mNGS clinical sample provided in Example 2 of the present application. DETAILED DESCRIPTION

[0042] In order to more clearly illustrate the contents disclosed in this application, including the purpose, technical solutions and advantages, we will use drawings and detailed descriptions to illustrate. The purpose of providing these embodiments is to make the understanding of this application more thorough and comprehensive.

[0043] Unless otherwise defined, all technical and scientific terms used herein are generally understood by those skilled in the art in the art of the present application. The terms used herein in the specification of the present application are only for the purpose of describing specific embodiments and do not limit the present invention.

[0044] Example 1

[0045] The specific embodiments of the present application provide a bioinformatics analysis method for detecting Mycoplasma pneumoniae and its 23S rRNA gene drug-resistant mutations, such as Figure 1 As shown, the following steps are included:

[0046] 1. Data preparation. The genomes or gene sequences used in this application include the Mycoplasma pneumoniae reference genome annotated by the NCBI database, the sequence of the 23S rRNA gene, the hg19 version of the human reference genome and transcriptome sequence, and the T2T-CHM13 human reference genome sequence; in addition, there are also the second-generation sequencing data of pathogen metagenomic (mNGS) clinical samples and negative control samples; the download links of each genome or gene sequence are shown in the following table:

[0047] Table 1. Download links for gene or genome sequences

[0048]

[0049] 2. In this application, fastp v0.23.2 was used to perform quality control on the original data of pathogen metagenomic (mNGS) sequencing, and the parameters were set to --dedup--length_required 45-q 20-n 1. First, the repeated sequences were removed, and then the reads containing N bases were filtered out, and the read fragments with a quality value lower than 20 were cut off. In addition, the adapter sequences and low-complexity sequences were cut off, and the sequences with a read length of less than 45bp after quality control were filtered out; in addition, for the entire sample, the sample was qualified only if it met the following three conditions: the Q30 base data volume accounted for more than 80%, the adapter contamination ratio was less than 1%, and the effective data volume after quality control must be greater than 70%.

[0050] 3. In this application, bowtie v2-2.4.4 is used to align the data after quality control to the human sequence database. The human sequence database consists of the hg19 version of the reference genome, transcriptome data (refMrna), the world's first Chinese standard genome sequence Yanhuang No. 1, and the gapless version of the human genome sequence T2T-CHM13 published in March 2022. The --un parameter is used to save the reads that cannot be aligned to the human sequence database, which are high-quality non-human sequences.

[0051] 4. In this application, bwa v0.7.17-r1188 was used to index the reference genome sequence of Mycoplasma pneumoniae, and the sequence after removing the human sequence was aligned with the reference genome sequence, and samtools v1.6 was used to sort and index the alignment results in bam format.

[0052] 5. If Figure 2 As shown, the present application uses the software samtools and combines the Python script written by the applicant to screen the comparison results from five aspects: sequencing quality value, alignment quality value (MAPQ value), number of reads, uniquely mapped reads, and foldchange value. If the comparison results meet the following conditions at the same time, it means that the sample is infected with Mycoplasma pneumoniae:

[0053] (1) The average sequencing quality value of the M. pneumoniae reference genome was greater than 30 and the number of reads with a mapping quality value greater than 30 was greater than or equal to 10;

[0054] (2) Only reads with an average sequencing quality value greater than 30 and a mapping quality value greater than or equal to 30 mapped to the M. pneumoniae reference genome are greater than or equal to 2, that is, the number of uniquely mapped reads is greater than or equal to 2;

[0055] (3) The Foldchange value is greater than or equal to 5; if there is no read detection that meets the above two conditions in the negative control sample, then

[0056] Foldchange is positive infinity.

[0057] The comparison sequences that meet the above conditions in the clinical samples are extracted and saved as Fastq format files to search for drug-resistant mutations.

[0058] 6. Use bwa v0.7.17-r1188 software to index the 23S rRNA gene sequence, and align the Mycoplasma pneumoniae alignment sequences that meet the conditions extracted according to the above steps to the 23S rRNA gene. Use samtoolsv1.6 to sort and index the alignment results, and generate the corresponding bam format file after processing.

[0059] 7. If Figure 3 As shown in the figure, bam-readcount v1.0.1 was used in combination with a self-written Python script to count the number of four bases A, C, G, T and N at the four sites 2063, 2064, 2067 and 2617 of the 23S rRNA gene from the bam file generated in step 6. N represents the uncertainty of the specific base during sequencing, and the sum of the numbers of ACGTN is the sequencing depth of the site. The following table is an actual single-end sequencing sample analysis result. The sequence number represents the 23S The sequence number of the rRNA gene, the second column represents the four sites that this application will focus on, the third column base refers to the base type of the corresponding site when no mutation occurs, the fourth column depth refers to the total depth of the corresponding site in the sample, and the five columns A, T, C, G, and N represent the statistics of the corresponding sites in the sample. Taking the column of G bases at site 2063 as an example, it is separated by colons, where 58 represents the number of G bases, the two 59.98s both represent the average map quality (MAPQ value), 36.78 represents the average base quality, 28 represents the number of positive chain reads, and 30 represents the number of negative chain reads.

[0060] Table 2. Example of single-end sequencing sample analysis results

[0061]

[0062]

[0063] 8. According to the established screening principles, write a Python script to screen credible mutation results from the base composition results. The specific screening principles are as follows:

[0064] (1) The proportion of mutation sites in a single chain (positive or negative chain) shall not exceed 90%;

[0065] (2) The mutation frequency is greater than or equal to 50% and the number of mutation reads is greater than or equal to 2;

[0066] (3) the mutation frequency is greater than or equal to 5% and less than 50%, the number of mutation reads is greater than or equal to 2, and the total depth of mutation sites is greater than or equal to 10;

[0067] A reliable mutation result is one that satisfies condition (1) and one of (2) and (3). In the above example, the total depth is 58, of which the positive strand is 28 and the negative strand is 30, satisfying condition (1). In addition, the mutation frequency is 100% and the number of mutation reads is 58, satisfying condition (2). Therefore, the sample has a mutation from A to G at position 2063.

[0068] Example 2

[0069] In order to evaluate the actual effect of the bioinformatics analysis method for detecting drug-resistant mutations in the 23S rRNA gene of Mycoplasma pneumoniae provided in the above Example 1, 10 clinical samples of pathogen metagenomics (mNGS) with known positive drug resistance of Mycoplasma pneumoniae were selected, and the mutation detection method provided by the present application and the commonly used mutation detection software VarScan2 on the market were used for analysis, and the comparison was made from the two aspects of detection accuracy and mutation analysis time. The specific comparison results are shown in the following table, from which it can be clearly seen that the mutation detection method provided by the present application is significantly higher in sensitivity than VarScan2, and takes less time.

[0070] Table 3. Comparison of the mutation detection method provided in this application with the analysis results of VarScan2

[0071]

[0072]

[0073] In addition, by observing the bam files after comparison through IGV software, the mutation information of drug-resistant sites can be clearly seen in all 10 samples, indicating that the method for detecting drug-resistant site mutations created by this application is very accurate; Figure 4 This is a screenshot of the LX2313876 sample at site 2063, from which it can be clearly seen that a mutation from A to G occurred at this site, which is completely consistent with the test results of this application.

[0074] Example 3

[0075] In order to evaluate the actual effect of a bioinformatics analysis method for detecting Mycoplasma pneumoniae and its 23S rRNA gene resistance mutation provided in the above-mentioned Example 1, the present application collected 13 bronchoalveolar lavage fluid samples from patients with known Mycoplasma pneumoniae infection positive but 23SrRNA gene resistance negative, and used the Illumina platform for high-throughput sequencing. The offline data were used to detect Mycoplasma pneumoniae and 23S rRNA resistance mutations using the method provided in the present application. It can be clearly seen from Table 4 that Mycoplasma pneumoniae was accurately detected in all 13 samples, with an accuracy rate of 100%; in addition, the 23SrRNA gene mutation detection method provided in the present application was used to analyze these 13 samples, and no mutations were detected; in addition, we also selected 30 negative control samples. Similarly, the method provided in the present application was used for detection, and Mycoplasma pneumoniae and 23S rRNA resistance mutations were not detected in the 30 negative samples, and the specificity reached 100%.

[0076] Table 4. Detection of Mycoplasma pneumoniae in 13 bronchoalveolar lavage fluid samples

[0077]

[0078]

Claims

1. A bioinformatics analysis method for detecting Mycoplasma pneumoniae and its 23S rRNA gene drug-resistant mutation, characterized in that: The following steps are involved: S-1. Prepare data including the Mycoplasma pneumoniae reference genome annotated in the NCBI database, the sequence of the 23S rRNA gene, the hg19 version of the human reference genome and transcriptome sequence, the Yanhuang No. 1 human genome, the T2T-CHM13 human reference genome sequence, mNGS clinical samples, and the second-generation sequencing data of negative control samples; S-2. Perform data quality control on the next-generation sequencing data of mNGS clinical samples and negative control samples; S-3. The quality-controlled data are compared with the human sequence database to remove human sequences; S-4. Align the sequence obtained in step S-3 to the reference genome of Mycoplasma pneumoniae, and process the comparison results using samtools software; S-5. Formulate the comparison sequence screening conditions and extract the sequences that meet the conditions from the comparison results of step S-4. The specific screening steps are as follows: (1) The average sequencing quality value of the M. pneumoniae reference genome is greater than or equal to 30 and the number of reads with a mapping quality value greater than or equal to 30 is greater than or equal to 10; (2) Only reads with an average sequencing quality value greater than or equal to 30 and a mapping quality value greater than or equal to 30 that are mapped to the Mycoplasma pneumoniae reference genome are greater than or equal to 2, that is, the number of uniquely mapped reads is greater than or equal to 2; (3) The ratio of the normalized read numbers of the clinical sample and the negative control sample is greater than or equal to 5; this ratio is the Foldchange value. If there is no read detection that meets the conditions in the negative control sample, the Foldchange is positive infinity; The sample homogenization method is as follows: Number of sequences after normalization = (20*N*0.000001) / sample size but: Foldchange = the number of clinical sample sequences after homogenization / the number of negative control sample sequences after homogenization; S-6. Align the alignment sequence that meets the screening conditions in step S-5 to the 23S rRNA gene to obtain an output file; S-7. Based on the output file of step S-6, count the number of four bases A, C, G, T and N at the four sites 2063, 2064, 2067 and 2617 of the 23S rRNA gene, where N represents the specific base that is uncertain during sequencing. The sum of the numbers of ACGTNs is the sequencing depth of the site; S-8. Formulate screening principles and screen the base composition results in S-7. The specific screening conditions include: (1) The proportion of mutation sites in a single chain should not exceed 90%; (2) The mutation frequency is greater than or equal to 50% and the number of mutation reads is greater than or equal to 2; (3) the mutation frequency is greater than or equal to 5% and less than 50%, the number of mutation reads is greater than or equal to 2, and the total depth of mutation sites is greater than or equal to 10; On the basis that condition (1) is met, if either condition (2) or condition (3) is met, the base composition result output by screening is a credible mutation result.

Citation Information

Patent Citations

  • Method for detecting resistant mutant of mycoplasma pneumoniae

    CN102002522A

  • Metagenome data analysis method for identifying drug-resistant gene and / or mutation site of drug-resistant gene and system thereof

    CN109686408A

  • Mycobacterium tuberculosis multi-line drug resistance gene identification method and device

    CN113621716A

  • Drug resistance gene identification method and system and electronic equipment

    CN114283886A

  • Method of preparing enriched sample for polypeptide sequencing

    CN114929897A